Biotech

Reports & Briefs 2 categories  Conferences  Conference Compendium See details Opportunities in Emerging Pharma Markets: Strategies for optimizing growth in key regions and therapeutic areas The flurry of recent industry acquisitions and alliances focused on product portfolios and distribution networks in the Emerging Markets underscores the attractiveness of these areas for the Pharmaceutical industry. This report outlines many of these recent industry alliances, by companies including Pfizer, GSK, Novartis, Abbott, Daiichi Sankyo and others. Many of these alliances have been focused on obtaining the Pharmaceuticals, Generics, Vaccines, OTC’s, Hepatitis and HIV/AIDS agents and Biosimilars appropriate for the Emerging markets. Other companies still seeking alliances are identified, as well as those that appear to be potential generic and Biosimilar supply partners. This report provides market forecasts for the major Emerging markets, by IMS and by key industry players. It also outlines the opportunities and challenges presented by market, the major companies focusing... See details Pricing and Reimbursement Strategies for Diagnostics: Overcoming reimbursement issues and navigating the regulatory environment Reimbursement for diagnostics is the key requirement for both the diagnostic providers and the payers because while 5-7% of the hospital cost is incurred on diagnostics, they are used for around 70% of the healthcare decisions. This top-selling report identifies novel pricing strategies to maintain a fair plane among all the stakeholders with this report. Our price: $ 3,835.00 See details The Future of the Biologicals Market: Market overview, innovations and company profiles Biopharmaceutical products are the key to the future of the pharmaceutical market. Even before the market stagnation seen in 2009 due to the recession, conventional pharmaceuticals were facing drastic consequences from the loss of patent cover for many blockbusters, and the continued failure of the R&D departments in big pharma to produce replacement candidates. Although the conventional, small-molecule segment of the market will continue to hold a larger share, their growth is expected to be in low single figures, while biopharma products are forecast to grow at rates up to 10% per annum. This report analyses the three main components of the biopharma market – monoclonal antibodies, therapeutic proteins and vaccines – to show why these groups have such a positive future. It provides the most up-to-date discussion of the whole biopharma market and explores new clinical indicat...